Skip to main content
. 2020 Feb 21;58(3):155–168. doi: 10.1016/j.resinv.2019.12.005

Fig. 3.

Fig. 3

A and B: CD13 mRNA (A) and protein concentrations in the ASL (B) of uninfected HNE cells pretreated with glycopyrronium (GLP), formoterol (FRM), ICI 118,551 (1 μM) plus formoterol (100 nM) (ICI + FRM), budesonide (BUD), a combination of these three drugs (GFB), or vehicle (Veh) for 72 h. C–F: Distribution of acidic endosomes exhibiting green fluorescence in HNE cells at 72 h after pretreatment with glycopyrronium (GLP) (D), formoterol (FRM) (E), a combination of the three drugs (GFB) (F), or vehicle (C). Data are representative of four different experiments. Scale bar = 100 μm. G: The fluorescence intensity of acidic endosomes in HNE cells at 72 h after pretreatment with glycopyrronium (GLP), formoterol (FRM), ICI 118,551 plus formoterol (ICI + FRM), budesonide (BUD), a combination of the three drugs (GFB), or vehicle (Veh), and in untreated cells (Untreated). The mean value of the fluorescence intensity of the vehicle-treated cells was set to 100%. A–G: The concentrations of glycopyrronium, formoterol, and budesonide were 100 nM. The results are presented as the mean ± SEM of five (A and B) or eight (G) subjects. Significant differences compared with cells pretreated with vehicle are indicated by *p < 0.05 and **p < 0.01 (A, B, and G). Significant differences compared with cells pretreated with formoterol are indicated by †p < 0.05 and ††p < 0.01 (A, B, and G). Significant differences compared with cells pretreated with glycopyrronium are indicated by ‡p < 0.05 (B).